HD Labs Semaglutide 10mg is a research-grade GLP-1 receptor agonist peptide sold in lyophilised 10 mg vials to South African laboratories for in vitro and preclinical work. SAHPRA confirmed in December 2024 that only registered semaglutide products (such as Novo Nordisk Ozempic) are authorised for human supply. Informal 2024 reseller pricing observed HD Labs vials at R780 per unit, though this predates current regulatory enforcement signalling.
Key Takeaways
- HD Labs Semaglutide 10mg is a lyophilised research peptide for in vitro and preclinical GLP-1 receptor studies, not for human use
- Semaglutide's C-18 acyl chain extends plasma half-life to 165–184 hours, enabling once-weekly dosing in clinical contexts
- Reconstitution: add 1.0 mL sterile diluent to produce a 10 mg/mL stock for serial dilution into assay buffer
- Comparable research-grade semaglutide products are certified at ≥98–99% HPLC purity; request batch-specific Certificates of Analysis before use
- SAHPRA's December 2024 position prohibits unregistered semaglutide supply for human use; research procurement requires institutional ethics approval and documented research-only intent
What Is HD Labs Semaglutide 10mg?
HD Labs Semaglutide 10mg is a lyophilised research peptide containing 10 mg of synthetic semaglutide per vial, supplied to South African laboratories for in vitro and preclinical GLP-1 receptor agonist studies. It is sold strictly research-use-only and is not a SAHPRA-registered medicine for human administration.
Semaglutide is a synthetic GLP-1 receptor agonist analogue with high sequence homology to native human GLP-1. Two chemical modifications extend its half-life: an Aib substitution at position 8 blocks DPP-4 cleavage, and a C18 fatty-acid acylation at position 26 (via a γGlu-2xOEG linker) drives reversible binding to serum albumin. These changes extend the plasma half-life to roughly 165–184 hours in human pharmacokinetic work. That long half-life makes the molecule useful as a once-weekly comparator in incretin research and as a reference ligand in GLP-1R binding assays.
The HD Labs format ships as a single 10 mg lyophilised powder vial. Add 1.0 mL sterile diluent to produce a 10 mg/mL stock, then serially dilute into assay buffer. Researchers comparing formats on this site can weigh the vial against the pre-mixed Body Pharm Semaglutide 6 Pen, or against the dual-agonist tirzepatide research peptide when designing GLP-1 versus GLP-1/GIP comparative protocols.
SAHPRA's December 2024 position is unambiguous: any semaglutide supplied for human use outside registered products (such as Novo Nordisk Ozempic) is unauthorised. Lyophilised vials of this type are lawful only within bona fide research contexts.
GLP-1 Receptor Binding: Mechanism Summary
Semaglutide activates the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Activation triggers Gαs-mediated adenylate cyclase activity, raising intracellular cAMP levels. PKA then phosphorylates downstream targets, potentiating glucose-stimulated insulin secretion in pancreatic β-cells.
Parallel signalling through hypothalamic GLP-1R populations suppresses appetite via POMC/CART neuron activation and AgRP inhibition. Peripheral vagal afferent GLP-1R engagement delays gastric emptying. Researchers running in vitro binding assays should note that most canonical mechanistic data was generated in rodent islets, transfected HEK-293 GLP-1R lines, and human clinical pharmacodynamic studies. Extrapolation to a specific cell model requires independent validation against a reference agonist.
Why the C-18 acyl chain matters
Native GLP-1(7-37) has a plasma half-life of roughly 1.5–2 minutes. DPP-4 cleavage at the Ala8 position and rapid renal clearance account for this short duration. Semaglutide's Aib8 substitution blocks DPP-4 proteolysis. The C-18 diacid fatty-acid chain attached at Lys26 via a γGlu-2xOEG linker drives reversible non-covalent binding to serum albumin, extending the human plasma half-life to approximately 165–184 hours and permitting once-weekly dosing intervals in clinical pharmacokinetic work.
In vitro, the same acylation reduces apparent free-drug concentration in albumin-containing assay buffer. Investigators titrating EC50 values in DMEM + 10% FBS should expect right-shifted dose-response curves relative to albumin-free media.
Translating clinical effect sizes to research design
The STEP 1 trial (Wilding et al., NEJM 2021) reported a 14.9% mean body-weight reduction at 68 weeks with 2.4 mg weekly subcutaneous semaglutide in human subjects. This clinical pharmacodynamic outcome cannot be reproduced in cell or tissue models and should not be cited as a research-chemical efficacy claim.
For benchtop work, the more useful anchor is receptor-level potency. Published GLP-1R binding affinities for semaglutide sit in the low-nanomolar range. This informs the concentration window for Body Pharm Semaglutide 6 Pen cross-format comparisons or head-to-head studies against the tirzepatide research peptide in GLP-1R versus GLP-1R/GIPR dual-agonist assays.
HD Labs Semaglutide 10mg: Product Specifications
HD Labs supplies semaglutide as a 10 mg lyophilised powder in a single sealed vial, intended for reconstitution immediately before in vitro use. Semaglutide is a 31-residue acylated GLP-1 analogue with a molecular weight of 4113.58 g/mol and CAS number 910463-68-2 (PubChem CID 56843331). Store unopened vials at −20 °C, desiccated and protected from light. General peptide stability literature supports up to 24 months in this state, though HD Labs does not publish a brand-specific stability dossier.
Reconstitution and working stocks
For benchtop work I reconstitute the 10 mg vial in 1.0 mL of bacteriostatic water or sterile PBS, giving a 10 mg/mL stock that is then serially diluted into assay medium. Volumes between 0.5 and 2.0 mL are acceptable depending on the desired stock concentration. Calculate the choice backward from the assay's working range, particularly for GLP-1R binding curves run in albumin-containing buffer where free-drug correction matters.
Reconstituted aliquots are stable for short periods at 2–8 °C. Longer storage warrants −20 °C single-use aliquots to avoid freeze-thaw degradation.
Purity benchmark
HD Labs markets the product as a high-purity research peptide, but no batch certificate of analysis was indexed at the time of writing, so a specific HPLC figure cannot be confirmed for this brand. Comparable research-grade semaglutide products are typically certified at ≥98–99% by HPLC. Polaris Peptides' semaglutide 10 mg is listed at >99% purity by HPLC-MS in 2024, and Cayman Chemical's reference material carries equivalent specification. Treat the ≥98% figure as a category benchmark until you obtain a batch-specific CoA from the supplier.
Researchers running cross-format work against the Body Pharm Semaglutide 6 Pen or comparative incretin studies with the tirzepatide research peptide should request CoAs for each lot to keep purity variables controlled.
South Africa Format Comparison: Semaglutide Options in 2026
For variable-concentration in vitro work the HD Labs 10 mg lyophilised vial is the more flexible procurement option. Pen formats such as the Body Pharm Semaglutide 6 Pen suit standardised dosing protocols where a fixed unit volume per administration simplifies preclinical workflow. The table below summarises the two formats available through South African suppliers as of 7 May 2026.
| Parameter | HD Labs Semaglutide 10 mg vial | Body Pharm Semaglutide 6 Pen |
|---|---|---|
| Format | Lyophilised powder, single vial | Pre-filled multi-dose pen |
| Semaglutide per unit | 10 mg | 6 mg (pen total) |
| Price (ZAR, May 2026) | ||
| Price per mg (ZAR) | Calculate from current quote | Calculate from current quote |
| Reconstitution flexibility | High, choose 0.5–2.0 mL diluent for any stock concentration | Low, fixed concentration set by manufacturer |
| Best research use case | In vitro GLP-1R binding curves, dose-response work requiring custom stock concentrations | Standardised preclinical dosing, repeatability studies, in vivo protocols with fixed unit volumes |
Confirm both ZAR figures directly from the supplier before purchase order sign-off. Informal social-media listings showed HD Labs 10 mg vials at around R780 in 2024, but that price predates current SAHPRA enforcement signalling around unregistered GLP-1 products and should not be assumed to hold in 2026. The full procurement page for the Body Pharm Semaglutide 6 Pen carries its own current pricing and CoA notes.
Researchers designing comparative incretin studies should also consider tirzepatide as the primary dual GIP/GLP-1 receptor co-agonist comparator. The tirzepatide research peptide listing covers format and purity details for that compound on the same supplier basis.
Research Applications: What Studies Use Semaglutide?
Semaglutide is used as a reference GLP-1 receptor agonist across five preclinical domains: glycaemic regulation assays, adipocyte metabolism, central nervous system signalling models, cardiovascular endpoint research, and incretin co-agonist comparator work. Every application described below assumes in vitro or preclinical use. HD Labs material is not authorised for human administration under SAHPRA's December 2024 position on GLP-1 products.
Glycaemic regulation work: Semaglutide is dosed onto pancreatic β-cell lines (commonly MIN6 or INS-1) to quantify glucose-stimulated insulin secretion, cAMP accumulation, and downstream PKA activation. Typical stock concentrations of 1–10 mg/mL are serially diluted into assay medium across nanomolar working ranges.
Adipogenesis protocols: 3T3-L1 or human primary adipocyte cultures measure lipolysis markers, GLUT4 translocation, and PPARγ expression following GLP-1R activation.
Neuroinflammation and hypothalamic signalling: This is a growing application area. Researchers probe arcuate nucleus POMC/AgRP populations, microglial activation markers, and blood-brain barrier transport of the acylated peptide.
Cardiovascular endpoint context (clinical, not preclinical): The SUSTAIN-6 trial reported a 26% reduction in major adverse cardiovascular events in type 2 diabetes patients on semaglutide versus placebo. This framed much of the subsequent mechanistic interest in endothelial GLP-1R expression and atherosclerotic plaque modelling.
Incretin co-agonist comparator design: The tirzepatide research peptide is the standard GIP/GLP-1 dual-agonist counterpart held alongside semaglutide on the bench. Researchers building triple-agonist comparisons typically add retatrutide (GLP-1/GIP/glucagon) as a third arm. For format-matched semaglutide comparisons within a single experimental run, the Body Pharm Semaglutide 6 Pen provides a fixed-concentration alternative to the HD Labs lyophilised vial.
Purity, Quality Assurance and CoA Documentation
A Certificate of Analysis (CoA) for a research-grade GLP-1 peptide should document, at minimum:
- HPLC purity (area-%)
- Mass spectrometry confirmation of the molecular ion against the theoretical 4113.58 Da semaglutide mass
- Water and counter-ion content
- Endotoxin and residual solvent results (where the supplier provides them)
Comparable suppliers list semaglutide at >99% HPLC-MS purity. Polaris Peptides (2024) and Cayman Chemical publish batch CoAs for semaglutide reference material. HD Labs does not publish a generic specification sheet in the indexed literature, so we treat its purity figure as batch-specific rather than catalogue-wide.
In receptor-binding and cAMP-accumulation assays, sub-percent impurities of truncated or des-amido semaglutide variants shift apparent EC50 values and inflate inter-run variability. This is the dominant source of irreproducibility in GLP-1R dose-response work.
JCSG.org batch-matching methodology
JCSG.org requests HPLC and MS-confirmed CoAs for every HD Labs batch prior to listing. Certificates are batch-numbered and dated. Researchers may request their batch CoA at checkout. Last process review: 7 May 2026.
For comparison studies, the Body Pharm Semaglutide 6 Pen ships with its own batch documentation. The Body Pharm tirzepatide research peptide is documented to the same standard for dual-agonist comparator arms.
Ordering, Shipping and Storage in South Africa
JCSG.org dispatches HD Labs semaglutide 10mg via tracked courier within South Africa, typically 2–5 business days to major metros (Johannesburg, Cape Town, Durban, Pretoria) and 3–7 days to outlying areas. Checkout is in ZAR with secure card payment. International shipping availability should be confirmed at checkout rather than assumed, given SAHPRA's December 2024 position on unregistered GLP-1 supply.
Packaging matters in a South African summer. Ambient temperatures in Gauteng and Limpopo regularly exceed 35 °C between November and February. Lyophilised semaglutide, while reasonably stable as a dry solid over short transit windows, should not be left in a hot vehicle or postbox. On receipt I transfer vials to −20 °C within 24 hours and log the receipt date against the batch CoA. Reconstituted stock (commonly 10 mg/mL in 1.0 mL sterile diluent for a 10 mg vial) is then aliquoted and stored according to the lab's SOP.
For format comparisons before ordering, the Body Pharm Semaglutide 6 Pen ships pre-filled rather than lyophilised. The Body Pharm tirzepatide research peptide follows the same cold-chain handling on arrival.
Regulatory and Legal Status in South Africa (2026)
Semaglutide for human therapeutic use is a Schedule 4 substance in South Africa under the Medicines and Related Substances Act 101 of 1965 (as amended), regulated by SAHPRA via sahpra.org.za. HD Labs semaglutide 10mg is supplied strictly as a research chemical for in vitro and preclinical laboratory use, not for human or veterinary administration, and is not a registered medicine.
SAHPRA's December 2024 position statement on GLP-1 and GIP/GLP-1 products confirms that only registered semaglutide products (such as Novo Nordisk's Ozempic, approved for type 2 diabetes) may be supplied for patient use. Compounded, unregistered, or falsified GLP-1 supply to the public is illegal. That approval is contextual only and confers no regulatory status on research-grade material. Any diversion of a research peptide into human use falls outside the lawful scope of sale.
Before procurement, I recommend researchers obtain written sign-off from their institutional ethics committee, register the compound on their chemical inventory, and verify their institution's procurement and biosafety policies. The same applies when ordering the Body Pharm Semaglutide 6 Pen or a tirzepatide research peptide for comparative incretin work. This section is not legal advice; consult a qualified regulatory advisor for case-specific guidance.
Related Research Peptides to Consider
Researchers building a comparative incretin or metabolic study around HD Labs semaglutide 10mg typically extend their panel with one or more of the following compounds.
Tirzepatide (dual GIP/GLP-1 agonist): Tirzepatide is the primary comparator for semaglutide in incretin co-agonism work, activating both GIP and GLP-1 receptors. A reported NEJM head-to-head (SURMOUNT-5, Jastreboff et al., 2025) is frequently cited in this context, but I have not been able to independently verify that citation and recommend confirming it on PubMed before quoting. The tirzepatide research peptide page lists the Body Pharm 30mg pen format for direct comparison.
Retatrutide (GLP-1/GIP/glucagon triple agonist): Retatrutide adds glucagon receptor activity on top of the dual-incretin profile, making it useful for studies dissecting energy expenditure and hepatic lipid handling alongside satiety endpoints.
Tirsema (combination format): Tirsema combines tirzepatide and semaglutide in a single vial, supporting protocols that examine additive or synergistic GLP-1 signalling without preparing two separate stocks.
Tesamorelin and IGF-1 LR3: Tesamorelin (a GHRH analogue) suits visceral-adiposity and body-composition arms. IGF-1 LR3 supports downstream insulin/IGF signalling experiments that pair logically with GLP-1 receptor work. For a direct same-molecule format comparison, the Body Pharm Semaglutide 6 Pen remains the closest in-category alternative.
Frequently Asked Questions
Q1: What is the difference between HD Labs Semaglutide 10mg and a 6mg pen format?
The HD Labs format is a 10mg lyophilised vial requiring researcher-supplied bacteriostatic water and self-mixing. The Body Pharm 6 Pen is a pre-configured pen delivering 6mg of semaglutide across metered doses. The vial gives full control over reconstitution volume and stock concentration; the pen trades that flexibility for dosing convenience. Price-per-mg typically favours the larger vial format, though exact ZAR figures should be confirmed from the live JCSG.org listing.
Q2: How should semaglutide research peptide be reconstituted for in vitro use?
Typical in vitro protocols reconstitute a 10mg vial in 0.5–2.0 mL of sterile solvent. A 1.0 mL volume of bacteriostatic water producing a 10 mg/mL stock is the most common convention. Add the diluent slowly down the vial wall and swirl gently to dissolve the lyophilised powder. Avoid vortexing, which can shear the peptide. Working dilutions should be calculated backward from the assay's target concentration range.
Q3: Is semaglutide legal to buy in South Africa for research?
Only registered semaglutide products such as Novo Nordisk's Ozempic are authorised medicines in South Africa, per SAHPRA's December 2024 position statement. SAHPRA explicitly warns against unregistered or compounded GLP-1 products supplied to the public. There is no separate carve-out for "research chemicals" in that notice, so procurement officers should document research-use-only intent and confirm their institutional ethics and Section 21 position before purchasing.
Q4: What purity level should I expect from HD Labs semaglutide?
HD Labs markets semaglutide as a high-purity research peptide. Comparable GLP-1 analogues in this category are typically certified at ≥98–99% HPLC purity. Polaris Peptides' 2024 semaglutide 10mg is listed at >99% by HPLC-MS as a reference benchmark. The specific HD Labs CoA figure should be requested from the supplier directly before citing a numeric value.
Q5: Can semaglutide be used alongside tirzepatide in a comparative receptor study?
Yes. Semaglutide (GLP-1 monoagonist) is the standard comparator for tirzepatide (GIP/GLP-1 dual agonist) in incretin pharmacology. Pairing the HD Labs vial with a tirzepatide research peptide supports parallel receptor-binding and downstream signalling assays. Match reconstitution buffers and stock concentrations across both arms to keep vehicle effects constant.
Next Steps
Request a batch-specific Certificate of Analysis from JCSG.org before finalising your purchase order. Confirm current ZAR pricing directly with the supplier, as informal 2024 figures no longer reflect market conditions. Obtain written institutional ethics approval and document your research-use-only intent on your chemical inventory. If you are designing a comparative incretin study, obtain CoAs for both the HD Labs semaglutide vial and your chosen comparator (such as the tirzepatide research peptide) to ensure purity variables are controlled across your experimental arms.
